143 related articles for article (PubMed ID: 29450445)
1. Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme.
Drahy F; Ingen-Housz-Oro S; Grootenboer-Mignot S; Wolkenstein P; Chosidow O
JAMA Dermatol; 2018 Apr; 154(4):487-489. PubMed ID: 29450445
[No Abstract] [Full Text] [Related]
2. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
Milrod CJ; Blevins F; Hughes D; Lerner A; Sarosiek S; Sanchorawala V; Sloan JM
Blood; 2021 May; 137(21):2987-2989. PubMed ID: 33728443
[No Abstract] [Full Text] [Related]
3. [Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients].
Cherouati K; Claudy A; Souteyrand P; Cambazard F; Vaillant L; Moulin G; Crickx B; Morel P; Lamorelle A; Revuz J
Ann Dermatol Venereol; 1996; 123(6-7):375-7. PubMed ID: 8959059
[TBL] [Abstract][Full Text] [Related]
4. Persistent erythema multiforme treated with thalidomide.
Chen CW; Tsai TF; Chen YF; Hung CM
Am J Clin Dermatol; 2008; 9(2):123-7. PubMed ID: 18284267
[TBL] [Abstract][Full Text] [Related]
5. [Lenalidomide desensitization in a patient with 5q- syndrome].
Boudin L; Patient M; Roméo E; Bladé JS; de Jauréguiberry JP
Bull Cancer; 2017 Sep; 104(9):814-816. PubMed ID: 28778340
[No Abstract] [Full Text] [Related]
6. Thalidomide as elective treatment in persistent erythema multiforme; report of two cases.
Conejo-Mir JS; del Canto S; Muñoz MA; Rodríguez-Freire L; Serrano A; Hernandez C; Pulpillo A
J Drugs Dermatol; 2003 Jan; 2(1):40-4. PubMed ID: 12852380
[TBL] [Abstract][Full Text] [Related]
7. Prevention of recurrent erythema multiforme with lenalidomide: a case series.
Ingen-Housz-Oro S; Joly P; Kini-Matondo W; Sbidian E
Clin Exp Dermatol; 2024 Jan; 49(2):166-168. PubMed ID: 37683088
[No Abstract] [Full Text] [Related]
8. Thalidomide treatment of recurrent erythema multiforme.
Bahmer FA; Zaun H; Luszpinski P
Acta Derm Venereol; 1982; 62(5):449-50. PubMed ID: 6183904
[No Abstract] [Full Text] [Related]
9. Exacerbation of psoriasis by thalidomide in a patient with erythema multiforme.
Varma K; Finlay AY
Br J Dermatol; 2006 Apr; 154(4):789-90. PubMed ID: 16536837
[No Abstract] [Full Text] [Related]
10. [Therapy of recurrent exudative erythema multiforme. Effectiveness of thalidomide--report of a case].
Engeser P; Klimm HD
Fortschr Med; 1999 May; 117(13):39-40. PubMed ID: 10365532
[TBL] [Abstract][Full Text] [Related]
11. Use of lenalidomide in treating refractory prurigo nodularis.
Liu H; Gaspari AA; Schleichert R
J Drugs Dermatol; 2013 Mar; 12(3):360-1. PubMed ID: 23545923
[TBL] [Abstract][Full Text] [Related]
12. Apremilast for treatment of recurrent erythema multiforme.
Chen T; Levitt J; Geller L
Dermatol Online J; 2017 Jan; 23(1):. PubMed ID: 28329479
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide-induced tubulointerstitial nephritis in Hodgkin lymphoma.
Dinh A; Palmer MB; Svoboda J; Hogan JJ
Leuk Lymphoma; 2019 Dec; 60(12):3084-3086. PubMed ID: 31125280
[No Abstract] [Full Text] [Related]
14. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
Fennira F; Chasset F; Soubrier M; Cordel N; Petit A; Francès C
J Am Acad Dermatol; 2016 Jun; 74(6):1248-51. PubMed ID: 27185425
[No Abstract] [Full Text] [Related]
15. Thalidomide for recurrent erythema multiforme.
Moisson YF; Janier M; Civatte J
Br J Dermatol; 1992 Jan; 126(1):92-3. PubMed ID: 1536771
[No Abstract] [Full Text] [Related]
16. Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide.
Chan TSY; Mak V; Kwong YL
Ann Hematol; 2017 Jul; 96(7):1211-1213. PubMed ID: 28432410
[No Abstract] [Full Text] [Related]
17. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Fürstenau M; Fink AM; Schilhabel A; Weiss J; Robrecht S; Eckert R; de la Serna J; Crespo M; Coscia M; Vitale C; Böttcher S; Weppner G; Ritgen M; Stilgenbauer S; Tausch E; Fischer K; Hallek M; Eichhorst B; Brüggemann M; Herling CD
Blood; 2021 Apr; 137(16):2267-2271. PubMed ID: 33512465
[No Abstract] [Full Text] [Related]
18. Long-term efficacy and safety outcomes of lenalidomide for cutaneous lupus erythematosus: A multicenter retrospective observational study of 40 patients.
Aitmehdi R; Arnaud L; Francès C; Senet P; Monfort JB; de Risi-Pugliese T; Barbaud A; Cohen-Aubart F; Haroche J; Pha M; Hie M; Le Guern V; Costedoat-Chalumeau N; Mékinian A; Fain O; Mathian A; Amoura Z; Chasset F
J Am Acad Dermatol; 2021 Apr; 84(4):1171-1174. PubMed ID: 33221461
[No Abstract] [Full Text] [Related]
19. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
[No Abstract] [Full Text] [Related]
20. Lenalidomide and thalidomide in the treatment of chronic pain.
Asher C; Furnish T
Expert Opin Drug Saf; 2013 May; 12(3):367-74. PubMed ID: 23442012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
